News Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Real-time Estimate Cboe BZX Other stock markets 01:29:33 2024-06-06 pm EDT			5-day change	1st Jan Change
8.035 ^USD	-0.06%		-26.29%	+208.39%

Jun. 03	Sector Update: Health Care Stocks Steady Premarket Monday	MT
Jun. 03	Stifel Adjusts Summit Therapeutics Price Target to $14 From $8, Maintains Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Steady Premarket Monday	Jun. 03	MT
Stifel Adjusts Summit Therapeutics Price Target to $14 From $8, Maintains Buy Rating	Jun. 03	MT
Transcript : Summit Therapeutics Inc. - Special Call	Jun. 03
Summit Therapeutics Generates $200 Million Through Share Sale; Expand License Territories for Ivonescimab	Jun. 03	MT
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab	Jun. 03	BU
Summit Therapeutics Inc. Expands License Territories for Ivonescimab	Jun. 03	CI
Summit Therapeutics Inc. announced that it expects to receive $199.999998 million in funding from Baker Bros. Advisors LP	Jun. 02	CI
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA	Jun. 01	BU
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy	May. 31	BU
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday	May. 31	MT
Wall Street Set to Open Modestly Higher Friday as Key Inflation Data Meets Expectations	May. 31	MT
Sector Update: Health Care	May. 31	MT
US Futures Trend Modestly Lower Pre-Bell Friday as Investors Await Key Inflation Report	May. 31	MT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 30	BU
Health Care Stocks Steady -- Health Care Roundup	May. 30	DJ
Summit Therapeutics Inc. Announces Phase III Clinical Trial, HARMONI-2 or AK112-303 Met its Primary Endpoint of Progression-Free Survival	May. 30	CI
US Equities Markets Close Lower Thursday After Q1 Economic Growth Found to be Slower Than Projected	May. 30	MT
Summit Therapeutics' Ivonescimab Beats Merck's Therapy in Lung Cancer -- Shares Soar	May. 30	MT
Summit Therapeutics Shares Triple After Drug Candidate Data	May. 30	DJ
Summit Therapeutics cancer therapy succeeds in late-stage China study	May. 30	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Summary

Filters